Mission Creek Capital Partners, Inc. Ascendis Pharma A/S Transaction History
Mission Creek Capital Partners, Inc.
- $397 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.51 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$741 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$641 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$627 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$585 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.33B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...